Which Men Do or Do Not Achieve Long-Term Symptom Relief After Holmium Laser Enucleation of the Prostate (HoLEP): 11 Years of HoLEP Experience.

Purpose: Apart from the existing level-one evidence, few centers have reported on long-term outcomes after Holmium Laser Enucleation of the Prostate (HoLEP). Against this backdrop we aimed to report on our treatment experience and identify predictors of persistent/recurrent lower urinary tract symptoms (LUTS) after the procedure. Materials and Methods: From 2006 to 2017, 2566 men underwent HoLEP at our institution. Only patients with available, cross-sectional follow-up (F/u) ≥6 months were included. Perioperative and F/u characteristics were compared by duration of F/u in months (quartiles). Multivariable logistic regression models (MVAs) were used to identify predictors of persistent/recurring symptoms, defined as International Prostate Symptom Score (IPSS) >7 at F/u. Results: A total of 774 patients with a median age of 70 years (interquartile range [IQR] = 66–75), prostate volume of 80 mL (IQR = 60–105), American Society of Anesthesiologists score 2 (IQR = 2–3), IPSS of 19 (IQR = 14–24), and quality of life (QoL) of 4 (3–5) at the time of operation were analyzed. Median F/u was 52 months (IQR = 32–77), overall current median prostate-specific antigen was 0.91 mg/dL (0.5–1.8), median IPSS and QoL were 3 (IQR = 1–7) and 1 (IQR 0–2), respectively. LUTS medication was present in 20 patients (2.6%), 15 (2%) patients required reoperation, and permanent urinary incontinence was present in 17 (2.2%) patients. On MVA age at operation (odds ratio [OR] = 1.04; 95% confidence interval [CI], 1.01–1.1; p = 0.013), prostate volume (OR = 0.99 [95% CI, 0.98–0.99;], p = 0.003), body mass index (OR = 1.06 [95% CI, 1.0–1.1], p = 0.043), presence of indwelling catheter (OR = 0.51 [95% CI, 0.32–0.81], p = 0.004), and anticholinergics before procedure (OR = 1.74 [95% CI, 1.01–3.0], p = 0.046) were predictors of persistent/recurring symptoms. Conclusions: Our HoLEP experience confirms durable and profound symptom relief in the vast majority men. A small fraction of patients complained about subjective persistent/recurring LUTS stressing the need for proper patient selection and timing of surgical intervention. [ABSTRACT FROM AUTHOR]